Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry Sells 3,259 Shares

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the sale, the chief financial officer now directly owns 75,805 shares of the company’s stock, valued at $2,070,234.55. This represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Stock Down 0.9 %

Shares of NYSE AORT traded down $0.22 during trading on Wednesday, hitting $25.34. The stock had a trading volume of 295,834 shares, compared to its average volume of 385,115. Artivion, Inc. has a 12 month low of $18.38 and a 12 month high of $32.33. The firm has a fifty day moving average of $29.68 and a two-hundred day moving average of $27.83. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market capitalization of $1.06 billion, a PE ratio of -1,268.25 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares in the last quarter. Quarry LP lifted its stake in Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the last quarter. R Squared Ltd purchased a new position in Artivion in the fourth quarter worth $39,000. Arcadia Investment Management Corp MI purchased a new stake in Artivion during the fourth quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Artivion during the fourth quarter worth $64,000. Institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on AORT. Oppenheimer raised their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC reduced their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.